Megan T. Sniecinski

2021

In 2021, Megan T. Sniecinski earned a total compensation of $7.9M as Former Chief Business Officer at BioCryst Pharmaceuticals, a 294% increase compared to previous year.

Compensation breakdown

Option Awards$6,952,056
Salary$286,192
Other$690,876
Total$7,929,124

Sniecinski received $7M in option awards, accounting for 88% of the total pay in 2021.

Sniecinski also received $286.2K in salary and $690.9K in other compensation.

Rankings

In 2021, Megan T. Sniecinski's compensation ranked 1,460th out of 12,415 executives tracked by ExecPay. In other words, Sniecinski earned more than 88.2% of executives.

ClassificationRankingPercentile
All
1,460
out of 12,415
88th
Division
Manufacturing
528
out of 5,505
90th
Major group
Chemicals And Allied Products
198
out of 2,375
92nd
Industry group
Drugs
164
out of 2,096
92nd
Industry
Biological Products, Except Diagnostic Substances
44
out of 449
90th

Pay ratio

Megan T. Sniecinski's Pay$7,929,124
Median Employee's Pay$273,522
Pay Ratio

29

to 1

In 2021, the annual total compensation of Megan T. Sniecinski was $7,929,124.

The annual total compensation of the median employee at BioCryst Pharmaceuticals was $273,522.

The ratio of Megan T. Sniecinski's pay to the pay of median employee was therefore 29 to one.

Source: SEC filing on April 25, 2022.

Sniecinski's colleagues

We found five more compensation records of executives who worked with Megan T. Sniecinski at BioCryst Pharmaceuticals in 2021.

2021

Jon Stonehouse

BioCryst Pharmaceuticals

Chief Executive Officer

2021

Helen Thackray

BioCryst Pharmaceuticals

Chief R&D Officer

2021

Anthony Doyle

BioCryst Pharmaceuticals

Chief Financial Officer

2021

William Sheridan

BioCryst Pharmaceuticals

Chief Medical Officer

2021

Yarlagadda Babu

BioCryst Pharmaceuticals

Chief Discovery Officer

News

In-depth

You may also like